144 related articles for article (PubMed ID: 11761814)
1. [Cancer procoagulant activity in cases of esophageal, stomach and colorectal cancer considering progression degree and histological type of cancer].
Kozuszko B; Skrzydlewski Z; Sulkowska M; Snarska J; Kozłowski M; Skrzydlewska E; Zalewski B
Pol Merkur Lekarski; 2001 Sep; 11(63):218-20. PubMed ID: 11761814
[TBL] [Abstract][Full Text] [Related]
2. Activity of cancer procoagulant (CP) in serum of patients with cancer of lung, breast, oesophagus and colorectum.
Rucińska M; Furman M; Skrzydlewski Z; Zaremba E
Acta Biochim Pol; 1997; 44(1):109-12. PubMed ID: 9241361
[TBL] [Abstract][Full Text] [Related]
3. [Diagnostic significance of cancer procoagulant activity in colorectal cancer].
Kozuszko B; Skrzydlewski Z; Famulski W
Pol Merkur Lekarski; 2000 Mar; 8(45):127-8. PubMed ID: 10870414
[TBL] [Abstract][Full Text] [Related]
4. Elevated serum synuclein-gamma in patients with gastrointestinal and esophageal carcinomas.
Liu C; Ma H; Qu L; Wu J; Meng L; Shou C
Hepatogastroenterology; 2012 Oct; 59(119):2222-7. PubMed ID: 22440249
[TBL] [Abstract][Full Text] [Related]
5. Cancer procoagulant as a marker in monitoring the therapy in cases of oesophageal, stomach and colorectal cancer.
Kozuszko B; Skrzydlewska E; Snarska J; Kozłowski M; Zalewski B; Skrzydlewski Z
Folia Histochem Cytobiol; 2001; 39 Suppl 2():104-5. PubMed ID: 11820560
[TBL] [Abstract][Full Text] [Related]
6. An enzyme-linked immunosorbent assay for cancer procoagulant and its potential as a new tumor marker.
Gordon SG; Cross BA
Cancer Res; 1990 Oct; 50(19):6229-34. PubMed ID: 2169340
[TBL] [Abstract][Full Text] [Related]
7. Comparison of peptide cancer signatures identified by mass spectrometry in serum of patients with head and neck, lung and colorectal cancers: association with tumor progression.
Pietrowska M; Polańska J; Suwiński R; Wideł M; Rutkowski T; Marczyk M; Domińczyk I; Ponge L; Marczak L; Polański A; Widłak P
Int J Oncol; 2012 Jan; 40(1):148-56. PubMed ID: 21894432
[TBL] [Abstract][Full Text] [Related]
8. [Diagnostic value of testing the procoagulant activity of neoplasms in cases of stomach and esophageal neoplasms].
Kozuszko B; Skrzydlewski Z; Kozłowski M; Snarska J
Pol Merkur Lekarski; 2001 Mar; 10(57):143-4. PubMed ID: 11398511
[TBL] [Abstract][Full Text] [Related]
9. Serum hyaluronic acid and laminin as potential tumor markers for upper gastrointestinal cancers.
Aghcheli K; Parsian H; Qujeq D; Talebi M; Mosapour A; Khalilipour E; Islami F; Semnani S; Malekzadeh R
Eur J Intern Med; 2012 Jan; 23(1):58-64. PubMed ID: 22153533
[TBL] [Abstract][Full Text] [Related]
10. Circulating Sex Hormones Are Associated With Gastric and Colorectal Cancers but Not Esophageal Adenocarcinoma in the UK Biobank.
McMenamin ÚC; Liu P; Kunzmann AT; Cook MB; Coleman HG; Johnston BT; Cantwell MM; Cardwell CR
Am J Gastroenterol; 2021 Mar; 116(3):522-529. PubMed ID: 33156012
[TBL] [Abstract][Full Text] [Related]
11. [Assessment of the efficacy of cancer procoagulant (CP) activity evaluation in the oncological diagnosis of the urinary system].
Szajda SD; Darewicz B; Kudelski J; Werel T; Zwierz K; Skrzydlewski Z; Gabrylewski W
Pol Merkur Lekarski; 2005 Oct; 19(112):596-9. PubMed ID: 16379335
[TBL] [Abstract][Full Text] [Related]
12. Cell proliferation, tumour growth and clinical outcome: gains and losses in intestinal cancer.
Rew DA
Ann R Coll Surg Engl; 1993 Nov; 75(6):397-404. PubMed ID: 8285542
[No Abstract] [Full Text] [Related]
13. [Evaluation of diagnostic values of neoplastic procoagulant in pancreatic, hepatic and ovary cancers].
Snarska J; Szajda S; Skrzydlewski Z; Kozuszko B
Pol Merkur Lekarski; 2003 Aug; 15(86):123-4. PubMed ID: 14648973
[TBL] [Abstract][Full Text] [Related]
14. Serum adiponectin levels in patients with esophageal cancer.
Yildirim A; Bilici M; Cayir K; Yanmaz V; Yildirim S; Tekin SB
Jpn J Clin Oncol; 2009 Feb; 39(2):92-6. PubMed ID: 19116211
[TBL] [Abstract][Full Text] [Related]
15. [The quantitative evaluation of the serum acute phase proteins (APP) of patients undergoing a curative resection for non-small cell lung cancer (NSCLC)].
Kasprzyk M; Dyszkiewicz W; Zwaruń D; Szydlik S; Leśniewska K; Krzyzanowski M
Przegl Lek; 2006; 63(10):936-40. PubMed ID: 17288188
[TBL] [Abstract][Full Text] [Related]
16. [Cancer procoagulant and cathepsin D activity in blood serum in patients with bladder cancer].
Szajda SD; Darewicz B; Kudelski J; Chlabicz M; Domel T; Chabielska E; Skrzydlewski Z
Pol Merkur Lekarski; 2005 Jun; 18(108):651-3. PubMed ID: 16124376
[TBL] [Abstract][Full Text] [Related]
17. Serum parathyroid hormone-related peptide is associated with systemic inflammation and adverse prognosis in gastroesophageal carcinoma.
Deans C; Wigmore S; Paterson-Brown S; Black J; Ross J; Fearon KC
Cancer; 2005 May; 103(9):1810-8. PubMed ID: 15800880
[TBL] [Abstract][Full Text] [Related]
18. Antioxidant potential in esophageal, stomach and colorectal cancers.
Skrzydlewska E; Kozuszko B; Sulkowska M; Bogdan Z; Kozlowski M; Snarska J; Puchalski Z; Sulkowski S; Skrzydlewski Z
Hepatogastroenterology; 2003; 50(49):126-31. PubMed ID: 12630007
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of examination of some tumor markers in diagnostics of liver cancer.
Snarska J; Szajda SD; Puchalski Z; Szmitkowski M; Chabielska E; Kaminski F; Zwierz P; Zwierz K
Hepatogastroenterology; 2006; 53(68):271-4. PubMed ID: 16608038
[TBL] [Abstract][Full Text] [Related]
20. [Hepatocyte growth factor in the sera of patients with gastrointestinal and breast cancer].
Narita T; Toi M; Sekiguchi K; Iwanari H; Matsuura N; Kimura N; Mitsuoka C; Kannagi R
Gan To Kagaku Ryoho; 1997 Nov; 24(14):2159-62. PubMed ID: 9388530
[No Abstract] [Full Text] [Related]
[Next] [New Search]
